By using our site you accept the terms of our cookie policy

Glancy Prongay & Murray LLP Announces An Investigation On Behalf of Spectrum

October 12, 2016


Glancy Prongay & Murray LLP Commences Investigation on Behalf of Spectrum Pharmaceuticals, Inc. Investors

GPM announces an investigation on behalf of Spectrum Pharmaceuticals, Inc. (“Spectrum” or the “Company”)  concerning the Company and its officers’ possible violations of federal securities laws.

The investigation concerns whether the Company misled investors regarding the FDA’s inquiry into whether data from the Spectrum 611 and 612 Studies were clinically meaningful; and whether the FDA advised defendants in December 2012 not to submit the New Drug Application based on data from the 611 and 612 Studies. Following the Company’s announcement that the FDA had denied approval for its apaziquone NDA the Company’s shares fell sharply in value.

If you purchased Spectrum securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email [email protected], or visit our website at If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact Us

+44 (0) 203 725 6841